1. What Is the Pharmacogenomics Market?
The Pharmacogenomics Market covers genetic testing services, laboratory platforms, clinical decision support software, and bioinformatics tools used to characterize individual genetic variants that influence drug metabolism, efficacy, and adverse reaction risk across therapeutic categories. Oncologists, cardiologists, psychiatrists, and primary care physicians use pharmacogenomics test results to select medications and optimize dosing for patients based on their cytochrome P450 enzyme genotype, drug transporter polymorphisms, and pharmacodynamic target variants. The market encompasses single-gene assays, multi-gene pharmacogenomics panels, comprehensive pharmacogenomic profiling platforms, and integrated electronic health record-linked clinical decision support tools deployed across hospital pharmacy, outpatient specialty, and population health management programs. FDA guidance on pharmacogenomics biomarkers and EMA pharmacogenomics guidelines inform labeling requirements for drug-gene interaction disclosures.
2. Pharmacogenomics Market Size & Forecast
3. Emerging Technologies
- Multi-gene pharmacogenomics panels analyze cytochrome P450 enzyme variants, drug transporter polymorphisms, and pharmacodynamic target genotypes from a single DNA sample to predict metabolism and response for dozens of commonly prescribed medications. Reference laboratory providers use next-generation sequencing or microarray platforms to generate pharmacogenomics profiles that integrate with electronic health record prescribing workflows via clinical decision support software.
- Clinical decision support software linked to pharmacogenomics genotype data alerts prescribing physicians and pharmacists to actionable drug-gene interactions at the point of prescribing, providing interpretation guidance on metabolizer status and dosing adjustment recommendations. Health systems implementing pharmacogenomics clinical decision support report reductions in prescriptions for drugs with predicted poor metabolism or high adverse event risk in genotyped patient populations.
- Liquid biopsy platforms applied to somatic pharmacogenomics enable detection of tumor-specific drug sensitivity variants from cell-free circulating tumor DNA without requiring tissue biopsy, enabling serial monitoring of emerging resistance mutations during cancer treatment. Guardant Health's Guardant360 assay and Foundation Medicine's FoundationOne Liquid CDx are deployed at oncology centers for companion diagnostic testing and therapy selection in breast, lung, and colorectal cancer.
- Pharmacogenomics data integration with artificial intelligence prescribing support tools enables population-level analysis of drug-gene interaction burden across health system patient panels, identifying high-risk patients for pre-emptive genotyping. Systems using machine learning on electronic health record data and genotype databases are being piloted at academic medical centers to prioritize which patients benefit most from pharmacogenomics panel testing.
Such innovations are driving change across adjacent industries too. Discover more in our Newborn Screening Market.
4. Key Market Opportunity
One of the most substantial opportunities in the Pharmacogenomics Market is the expansion of pre-emptive multi-gene pharmacogenomics testing from academic medical center pilots to large regional health systems and pharmacy benefit manager programs, where stored genotype data can generate recurring clinical decision support value across a patient's entire prescription history. The integration of pharmacogenomics testing into oncology electronic health record workflows through companion diagnostic approvals creates a recurring per-patient revenue stream for comprehensive genomic profiling platform providers supplying hospital oncology departments. The growing body of clinical evidence supporting psychiatric pharmacogenomics panel testing is enabling payer coverage expansion that unlocks large outpatient psychiatry prescribing volumes previously inaccessible to laboratory testing providers. As drug-gene interaction evidence accumulates for cardiovascular medications including warfarin, clopidogrel, and statins, cardiology pharmacogenomics testing is emerging as an incremental panel extension opportunity for reference laboratories already offering psychiatric and oncology pharmacogenomics services.
5. Top Companies in the Pharmacogenomics Market
The following organisations hold leading positions in the Pharmacogenomics Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Myriad Genetics
- Thermo Fisher Scientific
- Illumina
- Qiagen
- Agilent Technologies
- Bio-Rad Laboratories
- Luminex
- Genomic Health (Exact Sciences)
- Foundation Medicine (Roche)
- Tempus
6. Market Segmentation
The Pharmacogenomics Market is analysed across 5 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Product | Consumables and Reagents Instruments Software and Services |
| By Technology | PCR-Based Assays Microarray Next-Generation Sequencing Single Nucleotide Polymorphism Genotyping |
| By Application | Oncology Psychiatry and Neurology Cardiology Pain Management Infectious Disease |
| By End User | Hospitals and Specialty Centers Clinical Reference Laboratories Pharmaceutical Companies Academic Research Institutes |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Pharmacogenomics Market trajectory over the forecast period:
Oncology Pharmacogenomics Is Expanding Beyond Companion Diagnostics to Multi-Gene Tumor Profiling for Therapy Selection Across Cancer Types.Comprehensive genomic profiling assays that sequence hundreds of cancer-relevant genes from tumor tissue or liquid biopsy samples are replacing single-gene companion diagnostic tests for biomarker-driven oncology drug selection, providing oncologists with a full molecular portrait of the tumor at a cost approaching that of individual companion tests. The expansion from EGFR and KRAS single-gene tests to broad multi-gene panels reflects clinical evidence that tumors harbor multiple co-occurring and targetable alterations that sequential single-gene testing would miss. Foundation Medicine received FDA approval for its FoundationOne CDx comprehensive genomic profiling assay in 2017 as a companion diagnostic for multiple targeted therapies, enabling oncologists to identify mutations across 324 genes from a single tissue sample. The shift toward comprehensive profiling is increasing assay revenue per patient while reducing the total number of individual tests ordered, concentrating revenue growth among platforms with broad FDA companion diagnostic approvals.
Pre-Emptive Pharmacogenomics Testing Programs Are Gaining Adoption in Health System Formularies and Population Health Initiatives.Pre-emptive testing stores a patient's pharmacogenomics profile in the electronic health record before any drug prescription is written, allowing clinical decision support alerts to fire at the point of prescribing for any covered drug-gene interaction throughout the patient's care. Vanderbilt University Medical Center's PREDICT program and Mayo Clinic's RIGHT pharmacogenomics protocol demonstrated reduced adverse drug event rates and prescribing modifications in patients with actionable drug-gene interactions following systematic pre-emptive genotyping. Sanford Health launched a population-level pre-emptive pharmacogenomics initiative called Imagenetics in 2017, offering genomic profiling to patients across its health system for integration into longitudinal care records. The scale-up of pre-emptive testing from academic pilots to large health system deployments is driving multi-gene panel procurement from clinical reference laboratories and pharmacy benefit managers offering pharmacogenomics services to employer health plans.
Psychiatric Pharmacogenomics Is Achieving Payer Coverage for Panel Testing in Major Depressive Disorder and Anxiety as Clinical Evidence Accumulates.Psychiatric drug selection has historically relied on trial-and-error prescribing, and pharmacogenomics panels covering CYP2D6, CYP2C19, and CYP2C9 variants inform antidepressant and anxiolytic selection based on predicted metabolizer status. GeneSight Psychotropic, a combinatorial pharmacogenomics test from Myriad Genetics, received expanded commercial coverage from major US insurers following publication of the GUIDED randomized controlled trial in 2019, which demonstrated improved symptom improvement rates in patients whose prescribing was guided by pharmacogenomics versus standard of care. Payer coverage expansion for psychiatric pharmacogenomics testing is the primary commercial catalyst accelerating adoption in outpatient psychiatry and primary care mental health management. The addressable market in psychiatry is large, as antidepressant prescribing represents the most common drug-gene interaction category identified in pre-emptive pharmacogenomics panels.
For related market intelligence, see the Prenatal Testing Market.
8. Segmental Analysis
By application, the Oncology segment dominated the Pharmacogenomics Market in 2025, supported by FDA companion diagnostic approvals linking specific gene variants to targeted therapy eligibility across multiple tumor types and the broad adoption of comprehensive genomic profiling at cancer centers integrated with drug selection workflows. The Psychiatry and Neurology segment is the fastest-growing application category, expanding as clinical evidence from the GUIDED trial and similar studies supports payer coverage decisions and health system formulary adoption of pharmacogenomics-guided antidepressant prescribing.
By end user, Clinical Reference Laboratories led overall market revenue, while Pharmaceutical Companies are registering the highest growth rate as companion diagnostic co-development programs and biomarker-driven clinical trial enrollment generate increasing demand for pharmacogenomics testing services.
9. Regional Analysis
Regional demand patterns across the Pharmacogenomics Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Pharmacogenomics Market in 2025, accounting for approximately ~45% of global market revenue, driven by the FDA's pharmacogenomics biomarker guidance framework, the high density of academic health systems operating pre-emptive genotyping programs, and large reference laboratory networks offering multi-gene pharmacogenomics panels with integrated clinical decision support. Moreover, employer-sponsored health plan coverage of pharmacogenomics testing for psychiatric and oncology indications has expanded commercial payer reimbursement, enabling laboratory service providers to grow beyond institutional health system contracts into the broader commercial insurance market. In addition, the concentration of biopharma companies seeking companion diagnostic co-development partnerships with pharmacogenomics platform providers sustains a large pharmaceutical research segment within the North American market. The combination of regulatory infrastructure, academic program leadership, and commercial payer coverage sustains North American dominance in the Pharmacogenomics Market through the forecast period.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Pharmacogenomics Market through 2034, advancing at approximately ~18.5%, driven by China's Precision Medicine Initiative launched in 2016 allocating funding for genomic biobank development and drug-gene interaction research, Japan's national precision medicine programs integrating pharmacogenomics into oncology treatment guidelines, and South Korea's expanding clinical genomics laboratory sector. The region benefits from high prevalence of CYP2D6 and CYP2C19 allele variants in East Asian populations that create clinically significant drug metabolism differences relative to European reference populations, sustaining demand for population-specific pharmacogenomics testing. Moreover, regional genomics companies in China, South Korea, and Singapore are developing pharmacogenomics panel offerings at competitive price points for domestic hospital and outpatient pharmacy markets. The combination of government precision medicine investment, population-specific clinical need, and expanding laboratory infrastructure positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Pharmacogenomics Market was valued at USD 8.47 Bn in 2025 and is projected to reach USD 29.35 Bn by 2034, growing at a CAGR of 14.8% over the 2026–2034 forecast period.
The Pharmacogenomics Market is projected to grow at a CAGR of 14.8% from 2026 to 2034.
North America dominated the Pharmacogenomics Market in 2025, accounting for approximately ~45% of global market revenue, driven by the FDA's pharmacogenomics biomarker guidance framework, the high density of academic health systems operating pre-emptive genotyping programs, and large reference laboratory networks offering multi-gene pharmacogenomics panels with integrated clinical decision support.
The leading companies in the Pharmacogenomics Market include Myriad Genetics, Thermo Fisher Scientific, Illumina, Qiagen, Agilent Technologies, Bio-Rad Laboratories, Luminex, Genomic Health (Exact Sciences), Foundation Medicine (Roche), Tempus.
Oncology pharmacogenomics is expanding beyond companion diagnostics to multi-gene tumor profiling for therapy selection across cancer types.
By application, the Oncology segment dominated the Pharmacogenomics Market in 2025, supported by FDA companion diagnostic approvals linking specific gene variants to targeted therapy eligibility across multiple tumor types and the broad adoption of comprehensive genomic profiling at cancer centers integrated with drug selection workflows.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.